PBPH ETF Analysis

Diese Seite wurde per KI maschinell aus dem englischen Original übersetzt; die englische Fassung ist maßgeblich. Englische Fassung lesen

Nur zu Informationszwecken. Keine Finanzberatung.

Kurzantwort

PBPH ETF has a last stored price of $27.82, as of the Oct 2, 2026 trading session. Holdings and weights below are as of Mar 15, 2026.

In the stored portfolio snapshot, the largest listed holding is Eli Lilly and Co (LLY) at 13.85%.

PBPH ETF — Price, Holdings & Analysis

ETF-Übersicht

PBPH is designed to track the performance of the 10 largest global pharmaceutical companies. The ETF achieves this by holding a concentrated portfolio of leading firms in the pharmaceutical sector. As of 2026-03-15, its top holdings include Eli Lilly and Co (13.85%), Johnson & Johnson (9.35%), and AbbVie Inc (6.33%). The fund offers investors a targeted approach to investing in the global pharmaceutical industry, focusing on established, large-cap companies. This strategy differentiates PBPH from broader healthcare ETFs that may include a wider range of companies across various healthcare sub-sectors. PBPH's investment strategy is suitable for investors seeking concentrated exposure to the pharmaceutical industry's largest players. Past performance does not guarantee future results.

Risikokennzahlen

PBPH's introduces significant concentration risk. A substantial portion of the fund's assets is allocated to its top holdings, such as Eli Lilly and Johnson & Johnson, meaning the fund's performance is highly dependent on the performance of these few companies. The fund's sector focus on pharmaceuticals also exposes it to sector-specific risks, including regulatory changes, patent expirations, and drug pricing pressures. With a beta of 0.00, PBPH has historically shown very low volatility relative to the broader market. Investors should carefully consider their risk tolerance and investment objectives before investing in PBPH, given its concentrated nature and sector-specific risks. Past performance does not guarantee future results.

Beta: 0.00

Was hält PBPH?

Position	Gewichtung
Eli Lilly and Co (LLY)	13.85%
Johnson & Johnson (JNJ)	9.35%
AbbVie Inc (ABBV)	6.33%
Novartis AG Registered Shares (NOVN.SW)	5.32%
Roche Holding AG (ROG.SW)	5.27%
Merck & Co Inc (MRK)	4.89%
AstraZeneca PLC (AZN.L)	4.83%
Amgen Inc (AMGN)	4.56%
Gilead Sciences Inc (GILD)	3.98%
Pfizer Inc (PFE)	3.42%

Bestände und Gewichtungen zum 15. März 2026. Diese Fondsdaten sind älter als 45 Tage; prüfen Sie die aktuellen Bestände beim Emittenten.

Dividendenrendite

0.00%

Fragen & Antworten

What is PBPH and what does it track?

PBPH is an exchange-traded fund that aims to provide investors with targeted exposure to the largest global pharmaceutical companies. The fund achieves this by tracking an index composed of the 10 largest companies in the global pharmaceutical sector.

As of 2026-03-15, PBPH's top holdings include Eli Lilly and Co, Johnson & Johnson, and AbbVie Inc.

What are the top holdings in PBPH?

As of 2026-03-15, PBPH's top holdings are concentrated in leading global pharmaceutical companies. The top three holdings are Eli Lilly and Co (13.85%), Johnson & Johnson (9.35%), and AbbVie Inc (6.33%).

These companies represent a significant portion of the fund's assets, reflecting PBPH's strategy of focusing on the largest players in the pharmaceutical industry. Investors should be aware of the concentration risk associated with these top holdings.

Is PBPH a good long-term investment?

Whether PBPH is a suitable long-term investment depends on an individual investor's specific financial goals, risk tolerance, and investment horizon. PBPH offers targeted exposure to the global pharmaceutical industry, which may appeal to investors seeking growth in this sector.

However, the fund's concentrated portfolio and sector-specific risks should be carefully considered.

How does PBPH compare to similar ETFs?

PBPH distinguishes itself through its highly concentrated strategy of holding only the 10 largest global pharmaceutical companies. This contrasts with broader healthcare ETFs that may include a wider range of companies across various healthcare sub-sectors.

When comparing PBPH to similar ETFs, factors such as expense ratios, AUM, and investment strategies may be worth researching.

Does PBPH pay dividends?

According to the provided data, PBPH has a dividend yield of 0.00% as of 2026-03-15. This indicates that the fund does not currently distribute dividends to its shareholders.

Investors seeking income-generating investments may need to consider alternative ETFs with higher dividend yields. However, PBPH's focus on capital appreciation within the pharmaceutical sector may still be attractive to investors with different investment goals.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Führen Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Daten dienen ausschliesslich zu Informationszwecken.

Maschinell geschrieben, nicht Seite für Seite geprüft. Die redaktionelle Kontrolle ist systemisch: Regeln und Quellen werden geprüft, einzelne Seiten nicht.